Author:
Assouline S E,Chang J,Cheson B D,Rifkin R,Hamburg S,Reyes R,Hui A-M,Yu J,Gupta N,Di Bacco A,Shou Y,Martin P
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Siegel R, Ma J, Zou Z, Jemal A . Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9–29.
2. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphoma. V.4. 2014. https://www.nccn.org/store/login/login.aspx?ReturnURL=http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf .
3. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma. V.2. 2014. https://www.nccn.org/store/login/login.aspx?ReturnURL=http://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf .
4. Millennium Pharmaceuticals Inc VELCADE® (bortezomib) for Injection—Full Prescribing information, version 16. 2014. www.velcade.com/files/pdfs/velcade_prescribing_information.pdf .
5. O'Connor OA, Portlock C, Moskowitz C, Hamlin P, Straus D, Gerecitano J et al. Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clin Cancer Res 2010; 16: 719–726.
Cited by
48 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献